BenchSci vs Consensus

A preclinical program raises a specific kind of question before any experiment runs. A scientist wants to know what the published literature already says about a target, which reagents and model systems have been validated for it, and what the lab's own earlier studies found. Pulling those strands together usually means moving across several tools.

Both Consensus and BenchSci use AI to find and make sense of scientific literature. Consensus is an AI search engine for peer-reviewed literature that helps academics find and understand research. It searches roughly 200 million papers drawn mainly from OpenAlex and Semantic Scholar and reports use by more than 10 million researchers, students, and clinicians.

EMET by BenchSci is a specialized research platform for preclinical biology. Alongside published papers, it reasons over 16 million closed-access papers that BenchSci licenses from publishers, the largest reagent and model-systems database in the field. It runs proprietary scientific skills inside a team's own research workflows, so its agents answer from evidence on the target, the reagents, and the lab's prior results in one place.

This comparison measures the two on five criteria: the data each one reasons over, the depth of its biology-specific workflows and integrations, the service that drives adoption, the freedom to use the best model for each task, and whether the vendor develops drugs of its own. The two are evenly matched on model flexibility and on neutrality. On the other three, BenchSci pulls ahead.

What to look for in AI for preclinical R&D

Many AI tools for research can now read papers and return a cited summary in seconds, so it’s not immediately clear which platform will still carry a program a year from now. There are five traits to look out for that signal whether a platform is built to grow with your work.

• Proprietary, biology-specific evidence to reason over. An agent can only reason from the evidence it can reach. Access to curated biology that other platforms cannot use gives it more context on the target and safety questions that a program relies on.

• Depth of biology-grounded workflow and integration. Preclinical work runs from a literature question to an omics analysis to a decision at the bench. A platform is only useful if it has biology context and can plug into other systems where a lab stores its data.

• A service model that drives adoption. Buying a tool does not change how a lab works on its own. A tool is more likely to become part of daily research when it offers the right support for building workflows around a team's own projects.

• The freedom to use the best model for each task. No single model is best at every scientific job, and new ones ship every few weeks. A platform tied to one provider is limited by that provider's roadmap and pricing.

• A clear position on whether the vendor develops its own drugs. Your targets and results pass through this system. It is worth knowing whether the vendor could ever use what it learns to compete with you.

Few platforms do all five of these well. Each pulls in a different direction, from broad literature search to deep biology, hands-on services, model routing, and a neutral business model, so most tools are strong on one or two and thin on the rest. EMET and Consensus differ sharply across the five, and the sections below take each criterion in turn.

Criterion 1: The data and evidence the platform reasons over

Two systems with the same model will still reach different conclusions if one can see more of the evidence. An agent reasons only from the evidence that is available to it, so it’s important to consider the range of sources each platform's agents can actually read from.

Consensus searches a broad base of published, peer-reviewed literature

Consensus is strong on published research. Through its partnership with Semantic Scholar, it searches millions of peer-reviewed papers and uses language models to extract findings and show how much of the literature agrees on a question. Its reach is useful for a scientist scanning what has been published on a target.

That reach is mostly abstracts. For paywalled papers, Consensus typically sees the title and abstract only; full-text analysis is largely limited to open-access articles. It brings no proprietary licensed dataset of its own and no access to a lab's unpublished experimental data.

BenchSci reasons over closed-access biology and experimental data no one else holds

EMET draws on the same published literature, then adds a layer BenchSci spent a decade building. The platform reasons over a biological knowledge graph of 858 million nodes and 2.2 billion relationship edges, built from 38 million+ publications. It also reads the full text of 16 million closed-access papers licensed through eight years of partnerships with publishers such as Elsevier, Springer Nature, Wiley, and Oxford University Press, and those papers are available in EMET and nowhere else.

Under that literature sits the largest reagent and model-systems database anywhere: 16 million antibodies, 22 million RNAi entries, 18 million CRISPR records, 500,000 cell lines, and 700,000 animal models. A team of 60 PhD scientists curates the data. That layer answers the practical questions behind an experiment, such as which antibody has been validated in which model system.

EMET also reasons over your own data, including ELN entries, study reports, and structured systems, and keeps it isolated to your organization. A neuro-symbolic evaluation loop checks each claim against the knowledge graph and reaches 95%+ accuracy on biological questions.

Consensus reads the abstracts of published literature well. EMET reads the full closed-access papers behind them, adds a curated reagent database, and layers your own records on top.

Criterion 2: Depth of biology-grounded workflow and integration

A preclinical decision draws on literature, omics data, safety signals, and a lab's own past experiments. Joining them usually falls to the scientist, but some platforms can take on part of that work, connecting research to the systems a research organization already runs.

Consensus is built for literature search and synthesis

Consensus does one job very well: research. Its research tools include Pro and Deep search modes for synthesized, cited answers (Deep runs an agentic, multi-step review and produces a long-form report), the Consensus Meter for how much of the literature agrees on a yes-or-no question, chat with individual papers, and Study Snapshots that pull out methods and findings. A scientist can move from a question to a set of cited papers quickly.

Those features stop at the literature. Consensus does not run omics analysis, bioinformatics pipelines, or experimental design, and it offers no live connections to the lab systems where a research organization records its work. The reading and synthesis happen inside the app, and the rest of the preclinical workflow stays outside it.

EMET runs the biology and connects it to the systems your lab runs on

Scientists lose much of their time finding and cleaning data scattered across thousands of sources. EMET carries 200+ proprietary scientific skills and 250+ agents and workflows, spanning the preclinical journey from target identification and validation through lead optimization, safety, and IND-enabling studies. It draws on 1,000+ databases and cites every claim to a PMID, database record, or URL.

The platform runs the analysis too. It runs bioinformatics pipelines such as FastQC and RNA-seq differential expression inside the conversation, retrieves ADMET data, and visualizes protein structures. It reaches into the lab as well, through self-driving lab connectivity that links computational hypotheses to automated lab infrastructure.

EMET connects live to ELNs and internal databases, with no data ingestion required for structured systems, and access follows your existing permissions. Each deployment adds custom agents shaped around the customer's therapeutic areas and internal workflows.

Consensus can answer research questions well. EMET extends research by running the preclinical science and ties it to an organization’s own systems.

Criterion 3: The service model that drives adoption

A platform only changes research if scientists adopt it for their real projects. For most organizations, that depends on someone doing the work of fitting the tool to each team. This criterion examines how much of that work is done by your team versus the platform.

Consensus relies on self-serve adoption

Consensus has reached a large user base quickly, reporting more than 10 million researchers, students, and clinicians across 12,500+ universities. Anyone can start with the hosted product online and it offers library access tie-ins and team plans for institutions. Adoption rests on individual scientists picking up a self-serve tool.

BenchSci embeds a dedicated scientific team in every account

BenchSci staffs each deployment with a dedicated team of forward-deployed PhD scientists who know your biology and your therapeutic areas. The team runs training, manages the change, and builds the connectors, agents, and workflows specific to your organization, and a value engineering team reports ROI continuously.

That team stays in place as a scientific partner after launch. Its work is to turn the way your programs actually run into workflows your scientists use every day.

Individual scientists can adopt either product quickly, but BenchSci provides dedicated people who make it work across a whole organization and remove the burden of enablement from an internal team.

Criterion 4: Model flexibility and vendor independence

The best model for a scientific task changes every few months. A platform worth committing to has to adopt the next one without asking customers to rebuild their work. Neither BenchSci nor Consensus relies on a single AI model.

Consensus runs on third-party language models

Consensus builds no foundation model of its own. Its research agent runs on OpenAI models, and it uses language models to classify study designs and extract findings, which leaves it free to adopt a stronger model as one appears.

BenchSci is model-agnostic and routes every task to the best model

EMET also builds no foundation model of its own, and it does not force you to choose one. It routes each step of a task to the best available model from a roster of over 40 frontier and specialized systems. The platform uses frontier models for open reasoning and specialized models such as ESM-2 and AbLang2 where sequence or structure is the question. It adds each new frontier model as it ships.

Neither platform ties your research to a single model it builds itself. Both can move to a better model as soon as one appears.

Criterion 5: Whether your AI partner also develops drugs

A research platform sees a program's targets, assay results, and failed experiments. That makes it fair to ask whether the vendor could ever turn what it learns into a drug program of its own. It is the second of the two criteria where the platforms are currently closely aligned.

Consensus is a research search company

Consensus has no drug program of its own, and nothing about its business points toward one. It builds and sells research tools, so the targets and results a scientist runs through it do not feed a competing pipeline.

BenchSci has committed never to develop its own drugs

BenchSci makes that posture a permanent commitment: it will never discover its own drugs. Your data stays isolated to your organization and is never used to train shared models. BenchSci is also SOC 2 Type II attested and compliant with GDPR, CCPA, and applicable US state privacy laws.

For a team weighing IP risk, both vendors sit on the tooling side of the industry. The separation between them runs through the data, the biology-specific workflows, and the service model.

Choosing between EMET and Consensus

Consensus is a strong choice for a scientist who wants fast, cited answers from published literature. It searches a broad corpus of peer-reviewed papers, it shows where the literature agrees, and it matches EMET on model flexibility, so it can pick up a stronger model as one ships, and on neutrality, since neither runs a drug program that could compete with your pipeline.

They differ most in how much of the rest of a preclinical program each one supports.

On the other three criteria, EMET is ahead. It reads the full text of closed-access papers and a reagent and model-systems database no other platform holds, so its answers rest on evidence competitors cannot reach. It runs the preclinical science and connects that work to the ELNs and internal databases where your organization records it, so a program moves from literature to analysis to the bench in one place. And BenchSci places a dedicated team of PhD scientists in every account, so the workflows fit how your programs actually run.

If your programs depend on evidence and analysis beyond what published literature contains, EMET by BenchSci is built for that work. Book a demo with the BenchSci team to learn how it works with your own targets.